The antitumor action of NK-1R antagonist drugs consists of inhibiting mitogenesis and promoting apoptosis of glioma cells, inhibiting angiogenesis by inhibiting both endothelial cell proliferation and VEGF, decreasing migration of tumor cells, counteracting blebbing formation, decreasing the expression of MMP-2 and MT1-MMP, and increasing E-cadherin in glioma cells, resulting in decreased migration and invasion (metastasis). This evidence concerns the gene CDH1 and central nervous system cancer.